Wedbush Maintains Neutral on Nektar Therapeutics, Raises Price Target to $95

Benzinga Newsdesk www.benzinga.com Positive 61.8%

Neg 0% Neu 0% Pos 61.8%

Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and raises the price target from $70 to $95.